Sagent: Kedaara, TA Associates vie for minority stake in Sagent Pharma

Kedaara Capital and TA Associates are in talks to acquire a significant minority stake in Sagent Pharma, valued at $500-600 million. Investment amounts are estimated between $150-200 million. Originally acquired by Ravi Penmetsa's Ellimist Singapore, Sagent specializes in generic injectables for the US market.